ABUS
Arbutus Biopharma Corporation (ABUS) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
ABUS has a large cash balance and minimal debt, giving it flexibility to fund development and operations.
Revenue base remains small relative to market cap, so long-term upside still depends on sustained commercialization and pipeline execution.
No material change this month.
Profitability
Margins are exceptionally strong, with gross margin near 100% and operating margin above 80%.
Return on equity and return on invested capital remain very high, indicating efficient capital use.
No material change this month.
Financial Strength
The balance sheet is extremely liquid, with a current ratio above 80x and cash ratio above 5x.
Debt is effectively negligible, and solvency metrics remain very strong.
No material change this month.
Valuation
The stock trades at a premium sales multiple, which still requires continued growth and execution to justify.
Profitability supports a reasonable earnings multiple, but negative free cash flow keeps valuation less compelling on cash-based measures.
No material change this month.
Execution Risk
Cash flow remains negative despite strong accounting earnings, which creates a disconnect investors need to monitor.
Working-capital metrics are unusually distorted, suggesting the business may still have timing or collection risks.
No material change this month.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Arbutus Biopharma Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

